Carbamazepine Tablets USP, 200 mg have an estimated market size of US$ 32 million for twelve months ending December 2024 according to IQVIA
The approved product has an estimated market size of US$ 106 million for the twelve months ending October 2024, according to IQVIA
Sacubitril and Valsartan Tablets are indicated to reduce the risk of cardiovascular death
The product will be launched in March 2024
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure
According to IQVIA sales data for the 12-month period ending September 2022, the Gilenya Capsules, 0.5 mg market achieved annual sales of approximately US $1.8 billion
Strides is the first Indian company to get approval for the product.
Subscribe To Our Newsletter & Stay Updated
